PharmaShots | Incisive News in 3 Shots

Subscribe Now

SB15

Samsung Bioepis Reports the Initiation of P-III Study for SB15 Proposed Biosimilar to Eylea (aflibercept)

Samsung Bioepis Reports the Initiation of P-III Study for SB15 Proposed Biosimilar to Eylea (aflibercept)

July 1, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us